Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 22, Issue 4, 1997, Pages 256-266

  Revicki, Dennis A ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Antipsychotic medication; Cost effectiveness analysis; Pharmacoeconomics; Quality of life outcomes; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

COST BENEFIT ANALYSIS; DECISION MAKING; DRUG COST; HEALTH CARE COST; HUMAN; MEDICAL CARE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 0030836560     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. 1993. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 15:917-26.
2. Awad AG, Voruganti LNP, Heslegrave RJ. 1997. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 11:32-47.
3. Baker F, Intagliata J. 1982. Quality of life in the evaluation of community support systems. Eval Program Plann 5:69-79.
4. Beasley CM, Tollefson GD, Tran PV, Satterlee W, Sanger T, Hamilton S, and the Olanzapine HGAD Study Group. 1996. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-23.
5. Becker M, Diamond R, Sainfort F. 1993. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res 2:239-51.
6. Bennett KJ, Torrance GW. 1996. Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven. p 253-66.
7. Bigelow DA, Brodsky G, Steward L, Olson M. 1982. The concept and measurement of quality of life as a dependent variable in evaluation of mental health services. In: Stahler GJ, Tash WR, editors. Innovative approaches to mental health evaluation. New York: Academic Press, p 345-66.
8. Campbell DT, Stanley JC. 1966. Experimental and quasi-experimental designs for research. Chicago: Rand McNally College Publishing; 84 p.
9. Canadian Coordinating Office for Health Technology Assessment. 1994. Guidelines for economic evaluation of pharmaceuticals in Canada. Ottawa: Canadian Coordinating Office for Health Technology Assessment.
10. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. 1993. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40.
11. Davies LM, Drummond MF. 1993. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 162:38-42.
12. Dickey B, McGuire TG, Cannon NL, Gudeman JE. 1986. Mental health cost models: refinements and applications. Med Care 24:857-67.
13. Drummond MF, Davies LM. 1991. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 7:561-73.
14. Drummond MF, Stoddart G, Torrance GW. 1987. Methods for the evaluation of health care programmes. Oxford: Oxford University Press; 182 p.
15. Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L. 1996. Clozapine eligibility among state hospital patients. Schizophr Bull 22:15-25.
16. Finkler SA. 1982. The distinction between costs and charges. Ann Intern Med 96:102-9.
17. Frankenburg FR, Zanarini MC, Cole JO, McElroy SL. 1992. Hospitalization rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 4:247-50.
18. Glazer W, Ereshefsky L. 1996. A pharmacoeconomic model of outpatient neuroleptic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 57:337-45.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. 1996. Cost-effectiveness in health and medicine. New York: Oxford University Press; 425 p.
20. Guest JF, Hart WM, Cookson RF, Lindstrom E. 1996. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 10:59-67.
21. Hamilton SH, Revicki DA, Genduso L, Tollefson G. 1997. Cost-efficacy of olanzapine compared with haloperidol treatment for schizophrenia: results from a randomized clinical trial. Bethesda (MD): MEDTAP International; 38 p.
22. Hargreaves WA, Shumway M. 1996. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 57(9 Suppl):66S-76S.
23. Heinrichs DW, Hanlon TE, Carpenter WT. 1984. The Quality of Life Scale: an instrument for rating the schizophrenic deficit symptoms. Schizophr Bull 10:388-98.
24. Hogan TP, Awad HG, Eastwood MR. 1983. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 13:177-83.
25. Honigfeld G, Patin J. 1990. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 41:882-5.
26. Jonsson D, Walinder J. 1995. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 92:199-201.
27. Laupacis A, Feeny D, Detsky A, Tugwell P. 1992. How attractive does a new technology have to be to warrant adoption and utilization? tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473-81.
28. Lehman A, Possidente S, Hawker F. 1986. The quality of life of chronic patients in state hospital and in community residences. Hosp Community Psychiatry 37:901-7.
29. Lehman AF, Burns BJ. 1990. Severe mental illness in the community. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven, p 357-66.
30. Lehman AF, Carpenter WT, Goldman HH, Steinwachs DM. 1995. Treatment outcomes in schizophrenia: implications for practice, policy, and research. Schizophr Bull 21:669-75.
31. Lipscomb J, Weinstein MC, Torrance GW. 1996. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, p 214-46.
32. Luce BR, Elixhauser A. 1990. Standards for socioeconomic evaluation of health care products and services. New York: Springer-Verlag; 184 p.
33. Luce BR, Manning WG, Siegel JE, Lipscomb J. 1996. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, p 176-213.
34. Malm U, May PRA, Deneker SJ. 1981. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. Schizophr Bull 7:477-87.
35. Marder SR, Meibach RC. 1994. Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-35.
36. Meltzer H, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B. 1993. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 150:1630-8.
37. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision model for schizophrenia. Am J Managed Care. Forthcoming.
38. Pauker SG, Kassirer JP. 1987. Medical progress-decision analysis. N Engl J Med 316:250-8.
39. Reid WH, Mason M, Toprac M. 1994. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 45:261-4.
40. Revicki DA. 1993. Health care technology assessment and health-related quality of life. In: Banta D, Luce BR, editors. Health care technology assessment: an international perspective. New York: Oxford University Press, p 114-31.
41. Revicki DA, Genduso L, Hamilton S, Martin C, Reblando J, Tran P. 1996a. Quality of life outcomes of olanzapine and haloperidol treatment for schizophrenia and other psychotic disorders. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, NY. p 184-5.
42. Revicki DA, Luce BR. 1995. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 31:57-65.
43. Revicki DA, Luce BR, Weschler J, Brown RE, Adler MA. 1990. Cost-effectiveness of clozapine for treatmentresistant schizophrenic patients. Hosp Community Psychiatry 41:850-4.
44. Revicki DA, Murray M. 1994. Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1:465-76.
45. Revicki DA, Shakespeare A, Kind P. 1996b. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 11:101-8.
46. Rosen A, Pavlovic H, Parker G. 1989. The Life Skills Profile: a measure assessing function and disability in schizophrenia. Schizophr Bull 15:325-34.
47. Rosenheck RA, Massari L, Frisman L. 1993. Who should receive high-cost mental health treatment and for how long? Schizophr Bull 19:843-52.
48. Schooler N, Hogarty G, Weissman MM. 1979. Social Adjustment Scale Il (SASII). In: Hargreaves WA, Attkisson CC, Sorenson JE, editors. Resource materials for community health program evaluators. Washington (DC): US Department of Health, Education and Welfare, p 290-330.
49. Spilker B, editor. 1996. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven; 1051 p.
50. Stein LI, Test MA. 1980. Alternative to mental health treatment, I: conceptual model, treatment program and clinical evaluation. Arch Gen Psychiatry 37:392-7.
51. Stuart E, Wykes T. 1987. Assessment schedules for chronic psychiatric patients. Psychol Med 17:485-93.
52. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. 1997. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457-65.
53. Umbricht D, Kane JM. 1995. Risperidone: efficacy and safety. Schizophr Bull 21:593-606.
54. Weinstein MC, Fineberg HV. 1980. Clinical decision analysis. Philadelphia: WB Saunders; 351 p.
55. Wyatt RJ, Henter I, Leary MC, Taylor E. 1995. An economic evaluation of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 30:196-205.